Praxis Precision Medicines IncNASDAQ:PRAX
- LAST PRICE49.0750
- TODAY'S CHANGE (%)-1.0150 (-2.0264%)
- Bid / Lots48.8900/ 4
- Ask / Lots49.3300/ 4
- Open / Previous Close50.1500 / 50.0900
- Day Range
- 52 Week Range
- Volume50,605
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PRAX |
|---|---|---|
| 09:32 ET | 1041 | 50.15 |
| 09:36 ET | 510 | 52.2714 |
| 09:38 ET | 563 | 50.22 |
| 09:39 ET | 4362 | 50.43 |
| 09:41 ET | 360 | 49.64 |
| 09:48 ET | 100 | 50.095 |
| 09:50 ET | 150 | 50.124 |
| 09:57 ET | 223 | 49.38 |
| 09:59 ET | 100 | 49.4 |
| 10:08 ET | 524 | 48.9201 |
| 10:17 ET | 200 | 49.0673 |
| 10:26 ET | 181 | 49.1401 |
| 10:33 ET | 800 | 50.22 |
| 10:35 ET | 436 | 49.9373 |
| 10:42 ET | 685 | 49.605 |
| 10:46 ET | 100 | 49.75 |
| 11:02 ET | 100 | 49.4625 |
| 11:06 ET | 200 | 49.21 |
| 11:11 ET | 100 | 49.6 |
| 11:49 ET | 200 | 49.175 |
| 11:51 ET | 200 | 49.26 |
| 12:02 ET | 100 | 49.45 |
| 12:09 ET | 106 | 49.04 |
| 12:14 ET | 564 | 48.995 |
| 12:16 ET | 655 | 48.81 |
| 12:18 ET | 800 | 48.925 |
| 12:21 ET | 100 | 48.82 |
| 12:32 ET | 200 | 48.89 |
| 12:34 ET | 100 | 49.05 |
| 12:36 ET | 100 | 48.94 |
| 12:45 ET | 100 | 49.08 |
| 12:48 ET | 327 | 48.8714 |
| 12:54 ET | 200 | 49.09 |
| 12:59 ET | 1676 | 49.26 |
| 01:01 ET | 300 | 49.19 |
| 01:03 ET | 200 | 49.76 |
| 01:08 ET | 200 | 49.44 |
| 01:10 ET | 100 | 49.58 |
| 01:12 ET | 100 | 49.425 |
| 01:17 ET | 1200 | 49.715 |
| 01:19 ET | 100 | 49.6 |
| 01:21 ET | 140 | 49.72 |
| 01:26 ET | 100 | 49.72 |
| 01:28 ET | 100 | 49.72 |
| 01:30 ET | 400 | 49.31 |
| 01:39 ET | 100 | 49.63 |
| 01:48 ET | 200 | 49.36 |
| 01:50 ET | 800 | 49.585 |
| 01:51 ET | 200 | 49.515 |
| 01:53 ET | 100 | 49.34 |
| 01:55 ET | 300 | 49.5 |
| 02:00 ET | 300 | 49.51 |
| 02:02 ET | 100 | 49.47 |
| 02:04 ET | 600 | 49.36 |
| 02:08 ET | 100 | 49.315 |
| 02:13 ET | 1000 | 49.345 |
| 02:15 ET | 100 | 49.345 |
| 02:20 ET | 100 | 49.345 |
| 02:22 ET | 443 | 49.27 |
| 02:24 ET | 200 | 49.28 |
| 02:33 ET | 1305 | 49.25 |
| 02:36 ET | 300 | 49.25 |
| 02:38 ET | 700 | 49.075 |
Today
May 3, 2024
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:45PM ET on Friday May 03, 2024 by Dow Jones
4:45PM ET on Friday May 03, 2024 by Dow Jones
May 1, 2024
DJ Praxis Precision Med Initiated at Outperform by Baird, from 5:35AM ET on Wednesday May 01, 2024 by Dow Jones
5:35AM ET on Wednesday May 01, 2024 by Dow Jones
Apr 26, 2024
DJ Praxis Precision Med Price Target Maintained With a $105.00/Share by HC Wainwright & Co., from 7:16AM ET on Friday Apr 26, 2024 by Dow Jones
7:16AM ET on Friday Apr 26, 2024 by Dow Jones
Apr 12, 2024
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting, from 8:00AM ET on Friday Apr 12, 2024 by Dow Jones
8:00AM ET on Friday Apr 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Praxis Precision Medicines Inc | 856.9M | -2.1x | --- |
ALX Oncology Holdings Inc | 856.0M | -4.3x | --- |
Longboard Pharmaceuticals Inc | 855.0M | -9.0x | --- |
ARS Pharmaceuticals Inc | 852.7M | -15.2x | --- |
89Bio Inc | 867.5M | -4.3x | --- |
Viridian Therapeutics Inc | 887.8M | -3.1x | --- |
Company Information
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating insights from genetic epilepsies into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, is an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. Its product candidates include ulixacaltamide, PRAX-562, PRAX-628 and elsunersen.
Contact Information
- Headquarters
- 99 High Street, 30th FloorBOSTON, MA, United States 02110
- Phone
- 617-300-8460
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Dean Mitchell
- President, Chief Executive Officer, Director
- Marcio Souza
- Chief Financial Officer
- Timothy Kelly
- General Counsel, Corporate Secretary
- Alex Nemiroff
- Independent Director
- Jeffrey Chodakewitz
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $856.9M |
|---|---|
Revenue (TTM) | $2.4M |
Shares Outstanding | 17.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.86 |
EPS | $-23.64 |
Book Value | $7.92 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | 350.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5,164.41% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
